Menu

Henrietta Lacks’s Family Seeks Compensation

Family members of Lacks, the donor behind the widely used HeLa cell line, are planning to sue Johns Hopkins University.

Feb 16, 2017
Kerry Grens

WIKIMEDIA, EMWSeveral family members of Henrietta Lacks, the unwitting donor of tumor cells developed into the widely used HeLa cell line, say they were never compensated for the cells. They are now planning to sue Johns Hopkins University, which developed the cell line without Lacks’s permission several decades ago, according to The Baltimore Sun.

“Everyone else is making funds off of Henrietta’s cells,” Lacks’s grandson, Ron Lacks, told the Sun. “I am sure my grandmother is up in heaven saying, ‘Well, what about my family?’”

Johns Hopkins told the newspaper that the institution had never patented nor profited from the cells.

The Lacks story was documented in a book, The Immortal Life of Henrietta Lacks, which highlighted how the paucity of informed consent affected her family. In 2013, family members worked out a deal with the National Institutes of Health for the appropriate sharing of the HeLa genome with researchers. At the time, journalist Rebecca Skloot, who wrote The Immortal Life, told The Scientist that commercialization was discussed during negotiations between the Lackses and the NIH, but that science was the focus. “I was with the Lacks family as they did an interview the other day, and what they said basically was, ‘Money is not our big concern in this right now.’”

Lacks’s son Lawrence Lacks, who joins his son and daughter-in-law in asking for financial compensation, told the Sun he was not part of the agreement with the NIH. According to the newspaper, “the family said they want to her cells to be owned by her estate and they would set up a foundation to allow everyone to benefit from the cells.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.